Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines.

Adams JL, Badger AM, Kumar S, Lee JC.

Prog Med Chem. 2001;38:1-60. Review. No abstract available.

PMID:
11774793
2.

In vitro models for investigation of the effects of acute mechanical injury on cartilage.

Patwari P, Fay J, Cook MN, Badger AM, Kerin AJ, Lark MW, Grodzinsky AJ.

Clin Orthop Relat Res. 2001 Oct;(391 Suppl):S61-71. Review.

PMID:
11603726
3.

Identification and initial characterization of 5000 expressed sequenced tags (ESTs) each from adult human normal and osteoarthritic cartilage cDNA libraries.

Kumar S, Connor JR, Dodds RA, Halsey W, Van Horn M, Mao J, Sathe G, Mui P, Agarwal P, Badger AM, Lee JC, Gowen M, Lark MW.

Osteoarthritis Cartilage. 2001 Oct;9(7):641-53.

4.

Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models.

Ames RS, Lee D, Foley JJ, Jurewicz AJ, Tornetta MA, Bautsch W, Settmacher B, Klos A, Erhard KF, Cousins RD, Sulpizio AC, Hieble JP, McCafferty G, Ward KW, Adams JL, Bondinell WE, Underwood DC, Osborn RR, Badger AM, Sarau HM.

J Immunol. 2001 May 15;166(10):6341-8.

5.

IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase.

Kumar S, Votta BJ, Rieman DJ, Badger AM, Gowen M, Lee JC.

J Cell Physiol. 2001 Jun;187(3):294-303.

PMID:
11319753
6.

Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia.

Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, Legos JJ, Erhardt JA, Ohlstein EH, Hunter AJ, Harrison DC, Philpott K, Smith BR, Adams JL, Parsons AA.

Med Res Rev. 2001 Mar;21(2):129-45. Review.

PMID:
11223862
7.

Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis.

Badger AM, Blake S, Kapadia R, Sarkar S, Levin J, Swift BA, Hoffman SJ, Stroup GB, Miller WH, Gowen M, Lark MW.

Arthritis Rheum. 2001 Jan;44(1):128-37.

8.

SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.

Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, White RF, McVey MJ, Legos JJ, Erhardt JA, Nelson AH, Ohlstein EH, Hunter AJ, Ward K, Smith BR, Adams JL, Parsons AA.

J Pharmacol Exp Ther. 2001 Feb;296(2):312-21.

PMID:
11160612
9.

Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures.

Badger AM, Roshak AK, Cook MN, Newman-Tarr TM, Swift BA, Carlson K, Connor JR, Lee JC, Gowen M, Lark MW, Kumar S.

Osteoarthritis Cartilage. 2000 Nov;8(6):434-43.

10.

Injurious mechanical compression of bovine articular cartilage induces chondrocyte apoptosis.

Loening AM, James IE, Levenston ME, Badger AM, Frank EH, Kurz B, Nuttall ME, Hung HH, Blake SM, Grodzinsky AJ, Lark MW.

Arch Biochem Biophys. 2000 Sep 15;381(2):205-12.

PMID:
11032407
11.

Meniscal ossification in spontaneous osteoarthritis in the guinea-pig.

Kapadia RD, Badger AM, Levin JM, Swift B, Bhattacharyya A, Dodds RA, Coatney RW, Lark MW.

Osteoarthritis Cartilage. 2000 Sep;8(5):374-7.

12.

Inhibition of caspase-3-like activity prevents apoptosis while retaining functionality of human chondrocytes in vitro.

Nuttall ME, Nadeau DP, Fisher PW, Wang F, Keller PM, DeWolf WE Jr, Goldring MB, Badger AM, Lee D, Levy MA, Gowen M, Lark MW.

J Orthop Res. 2000 May;18(3):356-63.

PMID:
10937621
13.

Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies.

Bugelski PJ, Herzyk DJ, Rehm S, Harmsen AG, Gore EV, Williams DM, Maleeff BE, Badger AM, Truneh A, O'Brien SR, Macia RA, Wier PJ, Morgan DG, Hart TK.

Hum Exp Toxicol. 2000 Apr;19(4):230-43.

PMID:
10918514
14.

Amphibian Melanophore Technology as a Functional Screen for Antagonists of G-Protein Coupled 7-Transmembrane Receptors.

Nuttall ME, Lee JC, Murdock PR, Badger AM, Wang FL, Laydon JT, Hofmann GA, Pettman GR, Lee JA, Parihar A, Van Wagenen BC, Fox J, Gowen M, Johnson RK, Mattern MR.

J Biomol Screen. 1999;4(5):269-278.

PMID:
10838447
15.

Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality.

Lee D, Long SA, Adams JL, Chan G, Vaidya KS, Francis TA, Kikly K, Winkler JD, Sung CM, Debouck C, Richardson S, Levy MA, DeWolf WE Jr, Keller PM, Tomaszek T, Head MS, Ryan MD, Haltiwanger RC, Liang PH, Janson CA, McDevitt PJ, Johanson K, Concha NO, Chan W, Abdel-Meguid SS, Badger AM, Lark MW, Nadeau DP, Suva LJ, Gowen M, Nuttall ME.

J Biol Chem. 2000 May 26;275(21):16007-14.

16.

Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.

Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ, Stroup GB, Webb E, Rieman DJ, Gowen M, Boehm JC, Adams JL, Lee JC.

Arthritis Rheum. 2000 Jan;43(1):175-83.

17.

Down-regulation of chondrocyte aggrecan and type-II collagen gene expression correlates with increases in static compression magnitude and duration.

Ragan PM, Badger AM, Cook M, Chin VI, Gowen M, Grodzinsky AJ, Lark MW.

J Orthop Res. 1999 Nov;17(6):836-42.

PMID:
10632450
18.

Idoxifene, a novel selective estrogen receptor modulator, is effective in a rat model of adjuvant-induced arthritis.

Badger AM, Blake SM, Dodds RA, Griswold DE, Swift BA, Rieman DJ, Stroup GB, Hoffman SJ, Gowen M.

J Pharmacol Exp Ther. 1999 Dec;291(3):1380-6.

PMID:
10565864
19.
20.

Atiprimod (SK&F 106615), a novel macrophage targeting agent, enhances alveolar macrophage candidacidal activity and is not immunosuppressive in Candida-infected mice.

Badger AM, Handler JA, Genell CA, Herzyk D, Gore E, Polsky R, Webb L, Bugelski PJ.

Int J Immunopharmacol. 1999 Mar;21(3):161-76.

PMID:
10348366
21.

Applications of micro-CT and MR microscopy to study pre-clinical models of osteoporosis and osteoarthritis.

Kapadia RD, Stroup GB, Badger AM, Koller B, Levin JM, Coatney RW, Dodds RA, Liang X, Lark MW, Gowen M.

Technol Health Care. 1998 Dec;6(5-6):361-72.

PMID:
10100939
22.

SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.

Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Barnette MA, Grous M, Christensen S, Torphy TJ.

J Pharmacol Exp Ther. 1998 Nov;287(2):705-11.

PMID:
9808700
23.

SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes.

Badger AM, Cook MN, Lark MW, Newman-Tarr TM, Swift BA, Nelson AH, Barone FC, Kumar S.

J Immunol. 1998 Jul 1;161(1):467-73. Erratum in: J Immunol 1999 Mar 1;162(5):3105.

24.

Evaluation of the cutaneous anti-inflammatory activity of azaspiranes.

Griswold DE, Martin LD, Badger AM, Breton J, Chabot-Fletcher M.

Inflamm Res. 1998 Feb;47(2):56-61.

PMID:
9535542
25.
26.
27.

1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency.

Boehm JC, Smietana JM, Sorenson ME, Garigipati RS, Gallagher TF, Sheldrake PL, Bradbeer J, Badger AM, Laydon JT, Lee JC, Hillegass LM, Griswold DE, Breton JJ, Chabot-Fletcher MC, Adams JL.

J Med Chem. 1996 Sep 27;39(20):3929-37.

PMID:
8831759
28.

Disease-modifying activity of SK&F 106615 in rat adjuvant-induced arthritis. Multiparameter analysis of disease magnetic resonance imaging and bone mineral density measurements.

Bradbeer JN, Kapadia RD, Sarkar SK, Zhao H, Stroup GB, Swift BA, Rieman DJ, Badger AM.

Arthritis Rheum. 1996 Mar;39(3):504-14.

PMID:
8607900
29.

27-O-demethylrapamycin, an immunosuppressant compound produced by a new strain of Streptomyces hygroscopicus.

Box SJ, Shelley PR, Tyler JW, Verrall MS, Warr SR, Badger AM, Levy MA, Banks RM.

J Antibiot (Tokyo). 1995 Nov;48(11):1347-9. No abstract available.

30.

Biochemical and functional analysis of rat bronchoalveolar macrophages containing chemically induced phospholipid inclusions.

Waites CR, Bugelski PJ, Badger AM.

Toxicol Appl Pharmacol. 1995 Feb;130(2):316-21.

PMID:
7871542
31.

Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.

Albrightson CR, Bugelski PJ, Berkhout TA, Jackson B, Kerns WD, Organ AJ, Badger AM.

J Pharmacol Exp Ther. 1995 Feb;272(2):689-98.

PMID:
7853183
32.
34.
35.

Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors.

Lee JC, Badger AM, Griswold DE, Dunnington D, Truneh A, Votta B, White JR, Young PR, Bender PE.

Ann N Y Acad Sci. 1993 Nov 30;696:149-70. Review. No abstract available.

PMID:
8109825
36.

Divergent effects of rapamycin on mouse and rat cells following mitogenic stimulation.

Olivera DL, Kaplan JM, Newman-Tarr T, Ruggieri EV, Badger AM.

Clin Immunol Immunopathol. 1993 Sep;68(3):357-62.

PMID:
7690317
37.
38.

Beneficial effects of SK&F 105685 in rat adjuvant arthritis: prophylactic and therapeutic effects on disease parameter progression.

Badger AM, Swift BA, Webb EF, Clark RK, Bugelski PJ, Griswold DE.

Int J Immunopharmacol. 1993 Apr;15(3):343-52.

PMID:
8505147
39.

The azaspirane SKF 105685 ameliorates renal allograft rejection in rats.

Fan PY, Albrightson CR, Howell DN, Best C, Badger AM, Coffman TM.

J Am Soc Nephrol. 1993 Apr;3(10):1680-5.

40.

Therapeutic activity of SK&F 105685, a novel azaspirane with suppressor-cell inducing activity.

Badger AM, Swift BA.

Clin Exp Rheumatol. 1993 Mar-Apr;11 Suppl 8:S107-9.

PMID:
8324933
41.

Effects of SK&F 105685, a novel anti-arthritic agent, on immune function in the dog.

Kaplan JM, Badger AM, Ruggieri EV, Swift BA, Bugelski PJ.

Int J Immunopharmacol. 1993 Feb;15(2):113-23.

PMID:
8468115
42.
43.

SK&F 105685 treatment induces suppressor cell activity and modulates cell adhesion properties in rat recipients of cardiac allografts.

Schmidbauer G, Hancock WW, Badger AM, Kupiec-Weglinski JW.

Transplant Proc. 1993 Feb;25(1 Pt 1):758-60. No abstract available.

PMID:
8094912
44.

Effects of pyridinyl imidazole compounds on murine TNF-alpha production.

Olivera DL, Laydon JT, Hillegass L, Badger AM, Lee JC.

Agents Actions. 1993;39 Spec No:C55-7.

PMID:
8273586
45.

Beneficial effects of SK&F 105809, a novel cytokine-suppressive agent, in murine models of endotoxin shock.

Olivera DL, Esser KM, Lee JC, Greig RG, Badger AM.

Circ Shock. 1992 Aug;37(4):301-6.

PMID:
1446388
46.

Induction of suppressor cell activity in vivo and suppression of lymphoproliferative responses in vitro by SK&F 105.685 in the dog.

Thiem PA, Kaplan JM, Bugelski PJ, Ruggieri EV, Badger AM.

Immunopharmacology. 1992 Mar-Apr;23(2):67-74.

PMID:
1534791
47.

Regulation of colony-stimulating activity production from bone marrow stromal cells by the hematoregulatory peptide, HP-5.

King AG, Talmadge JE, Badger AM, Pelus LM.

Exp Hematol. 1992 Feb;20(2):223-8. Erratum in: Exp Hematol 1992 May;20(4):531.

PMID:
1544391
48.

SK&F 105685 suppresses allogeneically induced mononuclear and endothelial cell activation and cytokine production and prolongs rat cardiac allograft survival.

Hancock WW, Schmidbauer G, Badger AM, Kupiec-Weglinski JW.

Transplant Proc. 1992 Feb;24(1):231-2. No abstract available.

PMID:
1539260
49.

Inhibition of lymphoproliferative responses by SK&F 105685, a novel anti-arthritic agent.

Kaplan JM, Badger AM, Ruggieri EV, Olivera DL, Newman-Tarr T, Bugelski PJ.

J Clin Lab Immunol. 1991 Dec;36(4):49-58.

PMID:
1668843

Supplemental Content

Loading ...
Support Center